cGMP becomes a drug target.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 22297800)

Published in Naunyn Schmiedebergs Arch Pharmacol on March 01, 2012

Authors

Jens Schlossmann1, Elisabeth Schinner

Author Affiliations

1: Lehrstuhl für Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Regensburg, Universitätsstr. 31, 93040, Regensburg, Germany.

Articles cited by this

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science (1991) 9.99

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50

Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation (2011) 5.06

Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet (2011) 4.04

Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81

Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81

Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci (2010) 3.61

Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science (2007) 3.29

Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains. Science (1995) 3.18

The heart in human dystrophinopathies. Cardiology (2003) 2.97

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet (2010) 2.75

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48

Mechanical strain and bone cell function: a review. Osteoporos Int (2002) 2.10

Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol (2011) 1.85

Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci U S A (2011) 1.82

Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol (2010) 1.78

Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol (2007) 1.52

cGMP regulated protein kinases (cGK). Handb Exp Pharmacol (2009) 1.48

Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A (2010) 1.48

Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol (2009) 1.47

Regulation of canonical transient receptor potential isoform 3 (TRPC3) channel by protein kinase G. Proc Natl Acad Sci U S A (2004) 1.46

Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci U S A (2000) 1.36

Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem (2010) 1.34

Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res (2008) 1.34

Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci U S A (2010) 1.33

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28

cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. J Mol Biol (2007) 1.27

Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. Sci Signal (2009) 1.24

Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med (2012) 1.23

Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin (2009) 1.12

Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts. Sci Signal (2010) 1.11

Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. J Biol Chem (2009) 1.10

Cytidylyl and uridylyl cyclase activity of bacillus anthracis edema factor and Bordetella pertussis CyaA. Biochemistry (2010) 1.09

Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1. Biochemistry (2011) 1.05

Inhibition of TRPC1/TRPC3 by PKG contributes to NO-mediated vasorelaxation. Am J Physiol Heart Circ Physiol (2009) 1.04

Crystal structure of cGMP-dependent protein kinase reveals novel site of interchain communication. Structure (2011) 1.01

Nitric oxide-sensitive guanylyl cyclase is dispensable for nitrergic signaling and gut motility in mouse intestinal smooth muscle. Gastroenterology (2011) 1.00

Presynaptic nitric oxide/cGMP facilitates glutamate release via hyperpolarization-activated cyclic nucleotide-gated channels in the hippocampus. Eur J Neurosci (2011) 0.98

Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent protein kinase studied by small angle X-ray scattering in solution. J Biol Chem (1997) 0.97

Biomarkers of heart failure. Congest Heart Fail (2010) 0.96

Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated. FEBS Lett (2011) 0.95

A crystal structure of the cyclic GMP-dependent protein kinase I{beta} dimerization/docking domain reveals molecular details of isoform-specific anchoring. J Biol Chem (2010) 0.94

Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. Handb Exp Pharmacol (2009) 0.92

Long-term potentiation in the visual cortex requires both nitric oxide receptor guanylyl cyclases. J Neurosci (2007) 0.91

How We Learned to Say NO. Arterioscler Thromb Vasc Biol (2009) 0.91

Cyclic cytidine 3',5'-monophosphate (cCMP) signals via cGMP kinase I. FEBS Lett (2010) 0.90

CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep (2010) 0.89

Neuronal cGMP kinase I is essential for stimulation of duodenal bicarbonate secretion by luminal acid. FASEB J (2012) 0.88

Effects of cyclic GMP on the secondary structure of cyclic GMP dependent protein kinase and analysis of the enzyme's amino-terminal domain by far-ultraviolet circular dichroism. Biochemistry (1990) 0.86

Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases. Handb Exp Pharmacol (2009) 0.85

Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. Endocr J (2010) 0.83

Protein cysteine S-guanylation and electrophilic signal transduction by endogenous nitro-nucleotides. Amino Acids (2010) 0.83

A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide. Proc Natl Acad Sci U S A (2011) 0.83

Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.81

Functional regulation of transient receptor potential canonical 7 by cGMP-dependent protein kinase Iα. Cell Signal (2011) 0.78

Quantification of cAMP and cGMP analogs in intact cells: pitfalls in enzyme immunoassays for cyclic nucleotides. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.78